Ampersand invests in MedPharm

Financial details of the transaction remain undisclosed, though Ampersand typically invests $10-50m for majority and minority stakes in companies with turnovers of $10-100m. A new holding company has been created to facilitate the deal, according to publicly available documents.

Following the transaction, MedPharm will look to build out its executive team and undertake international expansion.

The deal comes in the same month that Ampersand held a final close for its ninth fund, Ampersand 2018, on $450m.

MedPharm founders Andrew Muddle and Marc Brown will remain with the company following the deal.

Company
Founded in 1999, Guildford-headquartered MedPharm provides formulation development, performance testing and clinical trials. The business tests and provides testing equipment for the development of drugs for the treatment of dermatological, ungual, nasal, lung, aural and other conditions. The business has additional operations in Durham, North Carolina.

People
Ampersand Capital Partners – David Parker (general partner).
MedPharm – Andrew Muddle (co-founder, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• UK / Ireland
• Healthcare
• United Kingdom